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Introduction
The massive increase in nucleotide sequence infor-
mation available in public and private databases,
coupled with advances in mass spectrometry (MS)
and the associated search algorithms, have provided
the basis for the emerging ﬁeld of proteomics. The
recent announcement of 35 000 or so genes in the
human genome was on the low side of the number
predicted. Yet, it re-afﬁrms the view that cellular
organisation is a complex system of protein com-
plexes and networks of gene products. As Walter
Blackstock (Glaxo-Wellcome, UK) pointed out ‘We
achieve our complexity not by sheer force of gene
numbers, but by the inﬁnitely subtle way in which
gene products interact’. As a newcomer to the ﬁeld
it is clear that proteomics is now coming of age. At
the end of the two day proteomics conference held
at the Basel Hilton, Switzerland, my overriding
impression was that momentum is gathering around
the globe to catalogue and characterise the proteins
encoded by the human genome, to compare varia-
tions in their expression levels under different
conditions, study their interactions, and identify
their functional roles. Proteomics on this scale
requires new technologies and techniques and
considerable effort is currently being devoted to
the development of novel tools of the trade.
2DE and alternative separation
techniques for proteome analysis
Whereas the conventional choice of two-
dimensional electrophoresis (2DE) as the means
for protein separation is open to discussion, there is
no signiﬁcant debate concerning the central role of
MS as the analytical technique of choice. The ﬁrst
session contained a series of talks which highlighted
the ability to interface mass spectrometry with a
range of protein separation methodologies and
established that sample preparation and presenta-
tion to the mass spectrometer play key roles in
determining the successful outcome of any pro-
teomics experiment.
The current and widely used method for protein
separation relies on excising spots from gels, protein
digestion, extracting the peptides produced and
analysing the peptides by MS or tandem MS. An
important limitation of the 2DE technology has been
the lack of very sensitive procedures to detect those
proteins that are present in very low abundance.
Reid Townsend described the 2DE based system
employed at Oxford Glycosciences (OGS), UK, for
high-throughput proteomic analysis of tissues and
body ﬂuids from normal and diseased individuals.
High abundance proteins which may obscure the
detection of proteins present in smaller amounts,
that generally represent targets or biomarkers, are
removed from body ﬂuids using a rapid, automated
process developed at OGS. A proprietary ﬂuores-
cent dye, used in conjunction with a novel ﬂuores-
cence scanner provides the basis of the OGS
imaging techniques and analysis of tandem mass
spectra is performed using the OGS database search
algorithm, SEAL.
Ed Hawkins (Amersham Pharmacia Biotech) pre-
sented the ﬂuorescence 2-D difference gel electro-
phoresis system (2D-DIGE), a technique whereby
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resolvable ﬂuorescent dyes so that they can be
mixed together, co-separated and visualised on a
single 2D gel for subsequent analysis. Running the
mixed protein sample on the same gel clearly
eliminates the problem of gel-to-gel variations. The
ﬂuorescent multiplexing of up to three proteins with
different ﬂuorescent dyes is compatible with mass
spectrometry and offers sub-nanogram sensitivity
for the analysis of 2D gels. Both these ﬂuorescence
detection procedures show a linear response to
variation in protein concentration over ﬁve or six
orders of magnitude and a broad dynamic range
provides more accurate quantitative data than
traditional 2D electrophoresis staining techniques.
General opinion seems to be that, at present,
2DE remains the method of choice for displaying
proteins for two main reasons; ﬁrst because it can
be used to visualise a very large number of proteins
simultaneously and, secondly, because it can be
used in a differential display format, enabling the
study of a biological system in its entirety rather
than as a multitude of individual components.
Limitations of the 2D analysis approach and
potential solutions to these problems were
addressed in a number of sessions. Methods of
preliminary fractionation of samples were described
to improve detection of low abundance proteins, as
was the use of very narrow range immobilised pH
gradient (IPG) strips for ﬁrst dimension separation.
The problem of detecting insoluble proteins is being
addressed by study of new solubilisation solutions,
including chaotropes and detergents, while to over-
come the difﬁculties in detecting very large and very
small proteins, people are looking to modify the
gels themselves.
The discussion of 2DE above shows that there is
room for improvement in the efﬁciency of pro-
teomic analysis. This may be achieved either by
advances in 2DE technology or through the devel-
opment of new technologies. One such new meth-
odology which moves away from a gel based system
is known as Isotope Coded Afﬁnity Tag (ICAT)
peptide labelling [4]. The method is based on a newly
synthesised class of chemical reagents (ICATs) used
in combination with tandem mass spectrometry. This
technique was discussed by Tim Nadler from Applied
Biosystems, USA, who have optimised the protocol
for derivatising and preparing samples with a
modiﬁed labelling reagent. The ICAT reagent con-
tains a biotin afﬁnity tag and a thiol-speciﬁc
reactive group, joined by a spacer domain, which
is available in two forms; regular and isotopically
heavy (includes eight deuterium atoms). Brieﬂy, the
reduced proteins of two different samples (control
versus treated) are ﬁrst labeled; one is derivatised
with the ICAT reagent containing the stable heavy
isotope and the other is labeled with the same
reagent containing the lighter natural isotopes. The
proteins are then mixed and proteolytically digested
to produce peptide fragments. The tagged cysteine
containing peptide fragments are isolated by avidin
afﬁnity chromatography, greatly reducing sample
complexity and decreasing the amount of time
required for MS/MS sequence analysis. An obvious
advantage of this approach over 2DE is the
potential for automation. Moreover, the technique
provides accurate relative quantiﬁcation of each
peptide identiﬁed since the standard and sample
peptide have the same sample ionization properties
and only differ in mass. Limitations of the system
include the fact that the proteins must ﬁrst of all
contain cysteine, which is true for approximately
80% of all proteins, and those cysteines must be
ﬂanked by appropriately spaced protease cleavage
sites.
Matthias Mann (MDS Proteomics, Denmark)
described a strategy of protein mixture analysis
utilising data dependent mass spectrometers to
generate as many peptides as possible from an
enzymatically digested protein mixture. In a ‘data-
dependent analysis’ the mass spectrometer measures
the masses of eluting peptides and those that meet
set signal threshold criteria are selected for frag-
mentation by the data system. Data-dependent
experiments are usually conducted on peptide
mixtures fractionated by reversed-phase liquid
chromatography connected on line with the mass
spectrometer. The procedure makes a complex
mixture approach feasible and, again, the potential
for automation is a key advantage. Moreover, the
system has a very wide dynamic range and
eliminates the problems of protein solubility asso-
ciated with 2DE since the proteins are all proteoly-
tically digested en masse.
Randall Nelson (Intrinsic Bioprobes Inc, USA)
described the combination of surface plasmon
resonance-biomolecular interaction analysis (SPR-
BIA) and MALDI-TOF MS to facilitate the study
of protein function and structure. The technology is
focused around a sensor chip plated with gold
(BIACORE). The molecule under study is attached
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solution is brought into contact with the surface.
When a protein binds, the change in mass concen-
tration close to the surface is measured in real time.
The power of this approach is the simultaneous
identiﬁcation of unknown binding partners and the
acquisition of data regarding the speciﬁcity, afﬁnity
and kinetics of the interaction. Recently SPR-BIA
has been combined with tandem MS in order to
sequence proteins bound to the sensor surface chip.
The proteins bound to the sensor chip are enzyma-
tically digested on the chip by delivering proteolytic
enzyme to the ﬂow cell via a microﬂuidics system.
To minimise the risk of sample loss the resulting
peptide mixture is then trapped in a capillary pre-
column by an on line recovery technique for
subsequent tandem MS analysis. The introduction
of this technique vastly improves the accuracy of
protein identiﬁcation in proteomic applications.
Functional Proteomics
Today, the term proteomics encompasses much of
the functional analysis of gene products or ‘func-
tional genomics’. In the short term, the goal of
functional genomics is to assign some element of
function to each of the genes in an organism and to
do this with high throughput. Long-term efforts will
focus on elucidating the organisation and control of
genetic pathways that come together to make up the
physiology of an organism. Knowledge of protein-
protein interactions helps place novel proteins in
their functional context. Walter Blackstock (Glaxo-
Wellcome, UK) suggested that Interaction or Cell
Map proteomics ‘will play an important role in
teasing out the protein complexes and networks of
gene products by which we achieve our cellular
complexity’.
In the majority of cases functional proteomic
approaches involve the isolation of a subset of
proteins from a given starting material through a
variety of afﬁnity-based methods (GST-fusion pro-
teins, antibodies, peptides, DNA, RNA or a small
molecule binding speciﬁcally to a cellular target).
Additionally, the enrichment afforded by afﬁnity
puriﬁcation facilitates the detection of low copy
number proteins and, monitoring a reduced subset
of proteins makes differences easier to detect in
differential display experiments. In his keynote
address, Matthias Mann described as an example
the puriﬁcation of the human spliceosome using
biotinylated RNA as the bait on which the complex
assembled [5]. Its protein components were then
displayed by 2DE and 19 new components identi-
ﬁed from a single gel. He went on to describe,
using the yeast nuclear pore complex Nup85p as an
example, how spatial organisation of multi-protein
complexes can be established through carefully
controlled cross-linking conditions to achieve cou-
pling of adjacent proteins. Components of speciﬁc
organelles have also begun to be analysed. Dr.
Mann described how work in collaboration with
Angus Lamond (Dundee) had so far identiﬁed more
than 200 nucleolar proteins of which 23% are novel.
Walter Blackstock outlined the tandem afﬁnity
puriﬁcation strategy (TAP) developed by Rigaut
et al. [8] which has been shown to improve complex
recovery and reduce non-speciﬁc protein binding.
The method involves double-tagging a known
protein component of a complex of interest and
introducing this construct into the host cell. The
native portion of the tagged protein then interacts
with cellular proteins, the complex is recovered
through two afﬁnity column steps and the compo-
nents are identiﬁed by MS and database searching.
Timothy Haystead (Duke University, USA and
Serenex, USA) outlined a functional proteomic
approach to identify bioactive ligands and their
physiological targets en masse. The technology
utilises naturally occurring bioactive molecules,
such as ATP, required in vivo to enable normal
cellular processes to occur. Whole tissue/cell extract
is passed through a ‘proteome mine’, in the case of
an ATP mine this consists of prepacked ATP
sepharose column cassettes. Following removal of
non-speciﬁcally bound proteins the columns are
successively washed with libraries of synthetic and
semi-natural product derived purine nucleotide
analogs and fractions collected and screened for
the presence of protein. The elution process is
repeated with additional library components (up to
10 structurally non-related components at a time).
Each proteome mine unit containing a 12 column
cassette can screen 1200 compounds per day if each
elution represents 10 library components. Fractions
containing protein are characterised by SDS-PAGE
and the proteins identiﬁed by mixed peptide
sequencing or MS. If the protein is deemed relevant
then the mining process will immediately generate a
lead compound and its physiological target. A
repertoire of resins is currently being developed as
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nucleotides (for DNA and RNA binding proteins),
Calmodulin (for Ca
2+ regulated proteins), and
microcystin (for protein phosphatases).
A number of biotechnology companies are gear-
ing up towards high-throughout methods for
identifying and characterising all of the proteins,
protein domains and protein interactions in a cell
using a functional proteomics approach. MDS
Proteomics (Denmark) has created an integrated
functional proteomics and drug discovery platform
to reveal cellular pathways, identify novel targets,
and discover new therapeutic drugs and diagnostic
products. Ron Hendrickson outlined MDSPs plat-
form strategy of identifying critical interactions
and targets using multiple ‘baits’ to isolate protein
complexes (PathMap
2), the use of LeadFinder
2 to
prioritise and quantitate hits and generate structural
information for drug discovery, and the storing and
interpretation of information for target selection
using the Biomolecular Interaction Network Data-
base (BIND). The BIND database (http://bioin-
fo.mshri.on.ca/cgi-bin/bind/dataman) is a publicly
available bioinformatics database that provides a
means of efﬁciently representing complex cellular
pathway information in silico. BIND will allow
researchers worldwide to submit and review results
of research deﬁned in three main data types:
interactions, molecular complexes, and pathways.
Dr. Donny Strosberg (Hybrigenics) described how
the company’s basic technologies are derived from
protein-protein interaction analyses using cell-based
methods such as the two-hybrid in yeast, in bacteria
techniques (bacterial two-hybrid), or biophysical
analysis based on BRET (Bioluminescence Reso-
nance Energy Transfer) technology. Using genomic
DNA from microbial pathogens or cDNA from
normal or diseased tissues, Hybrigenics strategy is
to identify interacting proteins, reconstitute func-
tional signaling or metabolic pathways and ﬁnally
identify modulators of these interactions which may
constitute lead compounds. Comprehensive Protein
Interaction Maps (PIMs) representing the interac-
tion network of the proteins of an organism or
between the proteins of two different organisms are
being created. Each interaction is evaluated and
given a reliability score. Hybrigenics’ approach of
two-hybrid screens reveals Selected Interacting
Domains (SIDs) which comprise the common part
of all overlapping prey fragments isolated in a
particular screen and contains the protein-protein
interaction domain. Hybrigenics then uses SIDs and
libraries of small molecules to identify lead com-
pounds capable of modulating interactions. The
strategy has recently been used to build up a large-
scale protein-protein interaction map of the human
gastric pathogen Helicobacter pylori [7].
Proteo-Informatics
High-throughput biotechnology calls for strong
bioinformatics tools in the form of powerful
biological data management systems and speciﬁc
algorithms for processing these data. Bioinformatics
pervades each step of the high-throughput proteo-
mic analyses outlined above. In all talks in this
session, speakers urged that this sort of manage-
ment of complex biological data is essential, now,
before the information accumulated becomes
overbearing.
The analysis of gel images to extract pertinent
biological information still represents a major
bottleneck in large-scale proteomics projects. Sonja
Voordijk (Geneva Bioinformatics) outlined the chal-
lenges for 2D gel analysis software with examples
of their product, Melanie 4, in action. The new
generation of software systems will not only have to
ensure high quality spot quantitation and accurate,
robust spot matching (which are the crucial steps in
2DE gel analysis), they will also have to enable the
handling of large volumes of 2DE data in an
automated way. In addition, they will need to
contain advanced statistical and classiﬁcation func-
tions and allow unlimited annotation capabilities
with the possibility to link and associate gel objects
to external equipment or data of any format located
locally or on the internet. Other image analysis
packages of note such as ImageMaster (Amersham-
Pharmacia Biotech) and Phoretix (Nonlinear
Dynamics) were presented in tutorial sessions.
The data management systems may be comple-
mented by information databases such as those com-
piled at Proteome, Inc., USA (http://www.proteome.
com/databases/index.html). James I. Garrels, talked of
Proteome’s provision of knowledge resources combin-
ing information on the proteins and genes of human,
mouse, rat and several other model organisms.
Proteome’s curators review scientiﬁc literature to
produce the proteome databases, which contain
indexed biological information on proteins and can
be used for annotating and interpreting experimental
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been generated which enable proteins to be grouped
according to their sequences with the assumption that
such clustering of proteins would lead to functional
grouping. In this way networks of functional linkages
between proteins in cells can be identiﬁed.
Protein Arrays
Ordered arrays of peptides and proteins provide the
basis of an alternative strategy to 2DE for parallel
protein analysis. A range of chip-based and array-
based technologies are emerging for the identiﬁca-
tion and characterisation of individual proteins and
for the proﬁling of protein expression in cells. At
Ciphergen Biosystems, USA, for instance, research-
ers have developed a technique called ProteinChip
in which a crude biological sample is placed on an
array capable of capturing a subset of proteins from
the sample. The array surface can be a chemical
surface with broad speciﬁcity so that it catches
whole classes of proteins. Or it can be extremely
speciﬁc, such as an antibody-, enzyme-, or receptor-
based surface that is highly selective for a few
proteins. After the capture step, the ProteinChip
array is washed and the proteins retained on the
surface are analysed by MS.
Proteome analysis of the simplest self-replicating
organism, Mycoplasma genitalium revealed an error
rate of at least 8% in the annotations for 340 genes
[9]. Ian Humphery-Smith (University of Utrecht and
Glaucus Proteomics) suggested that the experience
gained from such studies had taught many valuable
lessons and that efforts to tackle the complexity of
human beings could centre around non-traditional
approaches such as protein, peptide and antibody
arrays. A strategy of emulating the diversity
encoded by the genome through parallel generation
and screening of antibodies was discussed. The key
steps in large-scale antibody production including
the functionality of screening engines capable of
processing 50 000 000 ELISA-equivalents per day
per robot were outlined.
Recombinant antibodies are becoming increas-
ingly important in the ﬁeld of proteomics. Recent
advances include the development of large phage
antibody libraries that contain high afﬁnity binders
to almost any target, and new methods for
high throughput selection of antibody-antigen
interaction. Phage display is a method where
bacteriophage particles are made to express either
a peptide or protein of interest fused to a capsid or
coat protein. Lucy Holt (MRC LMB, UK) described
a novel technique for high-throughput screening of
recombinant antibodies, based on the creation of
antibody arrays. The method uses robotic picking
and high density gridding of bacteria containing
antibody genes followed by ﬁlter based ELISA
screening to identify clones that express antibody
fragments which bind the antigen(s) under test. By
eliminating the need for liquid handling, up to
18 342 different antibody clones can be screened at
a time and, because the clones are arrayed from
master stocks, the same antibodies can be multiply
spotted and screened simultaneously against up to
15 different antigens. Results so far suggest that the
antibody arrays can be used to identify differen-
tially expressed proteins [3].
Applications of proteomic analyses
Expression proteome analysis or Differential pro-
teomics compares the expression proﬁle of 2DE
separated proteins from an arbitrary reference state
of a cell, tissue, or organism, to the proﬁle of a non-
standard condition, such as a diseased state or after
the addition of a toxin to the system. Julio Celis
(Danish Centre for Human Genome Research,
Denmark) highlighted the potential of Expression
proteomics in the area of molecular medicine to
identify protein markers or protein patterns which
change in association with disease progression.
Such protein biomarkers can be used to identify
disease prior to the appearance of physical symp-
toms and distinguish between drug efﬁcacy and
toxic side effects, as well as identify new disease
pathways and drug targets. In one ongoing project,
Celis and colleagues have used proteome expression
proﬁles to reveal and identify proteins that are
differentially expressed in pure squamous cell
carcinomas (SCC’s) and normal urothelium of
bladder tumours and used them as ﬁngerprints to
subclassify histopathological types and as a starting
point for searching for protein markers. Speciﬁc
antibodies against the identiﬁed differentially
expressed proteins have been used to immunostain
serial cryostat sections of biopsies obtained from
SCC patients that have undergone removal of the
bladder due to invasive disease. So far these studies
have revealed markers for transitional cell carcino-
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bearing SCCs [6], and have led to the development
of a novel strategy for identifying premalignant
squamous lesions [1]. In the course of his talk the
difﬁculties of using human tissue to study proteins
were described and included preserving the state of
the proteins in the tissue sample and the hetero-
geneity of the tissue itself. A piece of tissue from an
organ or any part of the body contains numerous
different interacting cell sub-populations of which
only a tiny percentage of the total cells are diseased.
Consequently, there is a challenge to separate
out the subset of cells that are of interest either by
Laser Capture Microdissection or by enzymatic
digestion of the cells followed by a cell fractionation
process.
Another notable study described efforts to eluci-
date the molecular events leading to cardiac
dysfunction and was presented by John Weekes
(Imperial College of Science, Technology and Med-
icine, UK). Using a differential proteomic analysis,
Dr. Weekes and colleagues have demonstrated that
upregulation of the ubiquitin-proteasome system
of proteolysis occurs in dilated cardiomyopathy
(DCM). This leads to hyper-ubiquitination of a
number of cardiac proteins. Ubiquitinated proteins
were puriﬁed using S5a-Sepharose, afﬁnity chroma-
tography and separated using 2DE. All the iden-
tiﬁed ubiquitinylated proteins showed reduced
expression in DCM hearts indicating that inap-
propriate proteolysis of these proteins by the
proteasome may be a critical factor leading to loss
of normal cellular activity in the DCM heart and
ultimately to heart failure.
Concluding Remarks
Harnessing the available data in the post-genome
era is the major challenge facing many biological
scientists. Five years ago, when Mark Wilkins
coined the term proteome, few researchers were
even contemplating a wholesale protein discovery
effort on the scale of the human genome project.
Today, it’s a very different picture and the ﬁeld’s
aspirations have gained legitimacy. As is evident
from proteomic meetings such as this one, research-
ers are turning increasingly to the task of converting
the completed human DNA sequence into informa-
tion that will potentially improve, and perhaps
revolutionise human medicine and health care.
Advances in proteomic technologies which lead to
faster sample throughput and increased sensitivity
for the detection of individual proteins will facilitate
the realisation of this objective.
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